New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients.

about

Reduction in incidence of invasive fungal infection in patients receiving allogeneic stem cell transplantation using combined diagnostic-driven approach and itraconazole oral solution.

P2860

Q40475150-720AC567-72C9-4DC1-8C91-CD8502694D44

P2860

New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients.

Item

http://www.wikidata.org/entity/Q36222041

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

New agents for the prevention ...... em cell transplant recipients.

@ast

New agents for the prevention ...... em cell transplant recipients.

@en

type

Item

label

New agents for the prevention ...... em cell transplant recipients.

@ast

New agents for the prevention ...... em cell transplant recipients.

@en

prefLabel

New agents for the prevention ...... em cell transplant recipients.

@ast

New agents for the prevention ...... em cell transplant recipients.

@en

P1476

New agents for the prevention ...... em cell transplant recipients.

@en

P2093

David M Weinstock

http://www.w3.org/2001/XMLSchema#string

Gianna Zuccotti

http://www.w3.org/2001/XMLSchema#string

Lynne Strasfeld

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobia

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.

Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.

In vitro antifungal susceptibilities of Trichosporon species.

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.

Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis.

Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.

Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood a

P304

1669-1679

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.6.10.1669

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16086653

http://www.w3.org/2001/XMLSchema#string

New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients.

about

P2860

P2860

New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698